Notes
The study was funded by Millenium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Reference
Ailawadhi S, et al. Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. Clinical Therapeutics : 14 Feb 2019. Available from: URL: http://doi.org/10.1016/j.clinthera.2019.01.009
Rights and permissions
About this article
Cite this article
Comparing treatment costs for multiple myeloma. PharmacoEcon Outcomes News 823, 10 (2019). https://doi.org/10.1007/s40274-019-5700-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5700-5